Page 87 - Read Online
P. 87

eicosapentaenoic acid, docosapentaenoic  acid,     Traditional Chinese medicines
           and docosahexaenoic acid, protected against  the   It has been suggested that use of Chinese  herbal
           development of HCC, irrespective of HCV or HBV     medicines might  result in the protection of liver
           status.  The effect of treatment with high dose    function during chemotherapy.  [109]  The herbal
                 [97]
           purified long chain omega-3 fatty acids on liver fat   formulation PHY906 consists of four commonly used
           percentage and scores for liver fibrosis in patients   herbs,  i.e.  Scutellaria baicalensis Georgi,  Paeonia
           with  NAFLD  is  currently  being  investigated  in  a   lactiflora  Pall, Glycyrrhiza uralensis Fisch, and
           randomized double blind placebo controlled trial. [98]  Ziziphus jujube Mill, at a ratio of 3:2:2:2. Studies have
                                                              shown that PHY906 not only reduces gastrointestinal
           Spirulina platensis                                toxicity and enhances the antitumor efficacy of some
           Spirulina is a blue-green alga (cyanobacterium)    anticancer drugs but also alleviates chemotherapy-
           available as a dietary supplement. In vitro studies have   induced side effects, such as diarrhea. [109]  Preliminary
           demonstrated that spirulina may exert hepatoprotective   clinical  data indicate that PHY906  can serve as
           effects.  In patients with chronic hepatitis C infection,   an  adjuvant to  chemotherapy  in  the  treatment
                 [99]
           viral load and ALT levels tended to improve after 6 months   of advanced  HCC. [110]  Other traditional Chinese
           of treatment with spirulina in a small, active-controlled   medicines that may have a role in the treatment of
           trial. [100]   Another small, uncontrolled trial reported   HCC are bufotoxin (toad skin secretion), astragalus
           significant improvements in aspartate aminotransferase,   and products containing  ginseng  (Panax  ginseng),
           alanin aminotransferase, gamma-glutamyltransferase,   astragalus and mylabris (dried body of the Chinese
           triglycerides,  low-density  lipoprotein-cholesterol,   blister beetle). [111]
           total cholesterol, and the ratio of total cholesterol to
           high-density lipoprotein cholesterol after 6 months   CONCLUSION
           of treatment in patients with NAFLD. According to
           the  authors,  spirulina supplementation  resulted   Identifying  modifiable risk factors such as diet is
           also in a significant reduction in weight and insulin   important to counteract HCC. Dietary patterns are
           resistance, and a significant improvement in health-  complex to assess,  and are entangled with other
           related quality of life was observed. However, no   aspects of lifestyle.  To  date,  conclusive evidence
           changes in sonographic findings were observed. [101]  supporting a detrimental or beneficial role in the
                                                              prevention of chronic liver diseases is available only
           Antioxidants                                       for few products. Available information on coffee,
           Reduced glutathione (GSH) is a potent antioxidant   fish  and BCAAs  supplementation  is  of acceptable
           naturally occurring in the body, and is available for   quality  and supports a  beneficial  role  for these
           parenteral  administration.  Very  few  studies  have   products in the prevention and management of HCC.
           assessed the therapeutic role of GSH in liver diseases.    On the other hand, the detrimental effects of alcohol
           In an Italian study that compared the effects of reduced   and aflatoxins are widely recognized. Excessive sugar
           GSH and vitamin  K in  patients  with  alcoholic liver   and calorie consumption should also be avoided.
           disease, those treated with reduced GSH showed a
           greater improvement of hepatic function vs. patients   Financial support and sponsorship
           treated with vitamin K. [102]  A study published several   Nil.
           years ago assessed the effect of GSH treatment on HCC
           in 8 patients with biopsy-proven HCC not amenable   Conflicts of interest
           to surgery, but results were inconclusive. [103]  Besides   There are no conflicts of interest.
           direct GSH supplementation, hepatic GSH deposits   REFERENCES
           can be restored by administering compounds such
           as  S-adenosyl-L-methionine  and  N-acetylcysteine.   1.   Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci
           Both compounds are generally very well tolerated,     P, Musso A,  De Paolis P, Capussotti L, Salizzoni M,  Rizzetto  M.
           although of limited clinical value in improving liver   Expanding the natural history of nonalcoholic steatohepatitis: from
           function in chronic liver diseases. [104-106]         cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology
                                                                 2002;123:134-40.
                                                              2.   Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical
           Finally, it has been observed that patients with HCC   features  and  natural  history  of  nonalcoholic  steatosis  syndromes.
           have low levels of serum vitamin B [107]  and vitamin   Semin Liver Dis 2001;21:17-26.
           D, [108]  which suggests  that these  patients might   3.   Sacco R, Sivozhelezov  V, Pellegrini  L, Giacomelli  L, Longo  V.
                                                                 Dietary  supplementation  in  cancer  patients:  a  personal  view  of
           benefit from supplementation with these vitamins.     current status and future perspectives. Future Oncol 2014;10:1523-5.

            58                                                            Hepatoma Research | Volume 2 | March 9, 2016
   82   83   84   85   86   87   88   89   90   91   92